Denali Therapeutics Inc. DNLI Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s unrealized losses on investments (before tax)?
- Denali Therapeutics Inc. (DNLI) reported unrealized losses on investments (before tax) of $566K in Q1 2026.
- How has Denali Therapeutics Inc.'s unrealized losses on investments (before tax) changed year-over-year?
- Denali Therapeutics Inc.'s unrealized losses on investments (before tax) increased by 1517.1% year-over-year, from $35K to $566K.
- What is the long-term trend for Denali Therapeutics Inc.'s unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s unrealized losses on investments (before tax) has grown at a -4.4% compound annual growth rate (CAGR), from $25K to $20K.